Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.
OBJECTIVE
To evaluate the efficacy and tolerability of tolterodine extended release (ER) in men and women with overactive bladder (OAB).


METHODS
We analyzed data from two 12-wk, placebo-controlled trials of tolterodine ER (4mg QD). Patients completed 7-d bladder diaries and rated the urgency sensation associated with each micturition on a 5-point urgency rating scale. Micturitions were categorized by urgency rating: total (1-5), non-OAB (1-2), OAB (3-5), or severe OAB (4-5). Changes in micturitions during 24-h, daytime, and nocturnal intervals were assessed.


RESULTS
At baseline, 73% (547 of 745) of men and 57% (539 of 953) of women were continent. By week 12, tolterodine ER (n=848) reduced OAB and severe OAB micturitions during 24-h, daytime, and nocturnal intervals in both sexes compared with placebo (n=850). Adverse event rates were low and similar across treatment and gender.


CONCLUSIONS
In men and women with OAB, tolterodine ER reduced OAB and severe OAB micturitions, and was well tolerated.
Dmochowski
Roger
R
Vanderbilt University Medical Center, Nashville, TN, USA. roger.dmochowski@vanderbilt.edu
Abrams
Paul
P
Marschall-Kehrel
Daniela
D
Wang
Joseph T
JT
Guan
Zhonghong
Z
D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003408:Cresols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D016037:Single-Blind Method; D000068737:Tolterodine Tartrate; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate